The proteasome inhibitor Bortezomib (Velcade/PS-341) is an effective drug in the treatment of multiple myeloma and other tumours, mainly functioning by inhibition of the NF-κB survival pathway (reviewed by Boccadoro (Boccadoro et al, 2005)). The gene discussed is NFKB1; the disease is plasma cell myeloma.